Results 21 to 30 of about 37,294 (214)

Meta-analysis on the effects of octreotide on tumor mass in acromegaly. [PDF]

PLoS ONE, 2012
BACKGROUND: The long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to lower growth hormone (GH) levels in patients with acromegaly and may also induce pituitary tumor shrinkage.
Andrea Giustina, Gherardo Mazziotti, Valter Torri, Maurizio Spinello, Irene Floriani, Shlomo Melmed   +5 more
doaj   +1 more source

Pasireotide for the Medical Management of Feline Hypersomatotropism [PDF]

, 2015
BACKGROUND: Feline hypersomatotropism (HST) is a cause of diabetes mellitus in cats. Pasireotide is a novel multireceptor ligand somatostatin analog that improves biochemical control of humans with HST.
Abraham, Adams, Alt, Appleton, Bhayana, Bruns, Castillo, Church, Colao, Colao, Cuevas-Ramos, Fedele, Fernandez-Rodriguez, Fougner, Golor, Henry, Hofland, Juul, Katznelson, Kvols, Lamb, Lamberts, Maxwell, Meij, Miller, Murray, Myers, Niessen, Niessen, Niessen, Niessen, Petrus, Polska, Rand, Ray, Schmid, Schmid, Sheppard, Slingerland, Sohmiya, Starkey, Stolk, Taboada, Wajchenberg, Zatelli, Zou   +45 more
core   +2 more sources

Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial

Trials, 2011
Background Polycystic liver disease (PLD) is defined as having more than 20 liver cysts and can present as a severe and disabling condition. Most symptoms are caused by the mass effect of the liver size and include abdominal pain and distension.
Chrispijn Melissa, Drenth Joost PH
doaj   +1 more source

The effect of SRIH-14 or octreotide on the morphological characteristics of adrenal medulla using newcast [PDF]

Archives of Biological Sciences, 2010
The effects of chronic treatments with either SRIH-14 or octreotide on the adrenal medulla of male Wistar rats were examined. Adult males received subcutaneous (s.c.) injections of 20 μg/100 g body weight of either SRIH-14 or octreotide twice a day for ...
Trifunović Svetlana, Filipović B., Ajdžanović V., Manojlović-Stojanoski Milica, Nestorović Nataša, Sekulić Milka, Milošević Verica   +6 more
doaj   +1 more source

Pasireotide Long-Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism [PDF]

, 2017
BACKGROUND: Long‐term medical management of hypersomatotropism (HS) in cats has proved unrewarding. Pasireotide, a novel somatostatin analogue, decreases serum insulin‐like growth factor 1 (IGF‐1) and improves insulin sensitivity in cats with HS when ...
Abraham, Berg, Bruns, Church, Colao, Colao, Combes, Cozzi, Dowling, Dunning, Feelders, Freda, Gadelha, Henry, Hofland, Hubina, Hussaini, Jaffe, Katznelson, Kurosaki, Lamb, Laron, Ma, Meij, Meij, Myers, Niessen, Niessen, Niessen, Patel, Petersenn, Peterson, Reubi, Reusch, Reusch, Sathyapalan, Schaefer, Scudder, Shanik, Slingerland, Slingerland, Theodoropoulou, Tyson, Zambre   +43 more
core   +3 more sources

Octreotide in Intestinal Lymphangiectasia: Lack of a Clinical Response and Failure to Alter Lymphatic Function in a Guinea Pig Model

Canadian Journal of Gastroenterology, 2004
Intestinal lymphangiectasia, which can be classified as primary or secondary, is an unusual cause of protein-losing enteropathy. The main clinical features include edema, fat malabsorption, lymphopenia and hypoalbuminemia.
S Makhija, P-Y vod der Weid, J Meddings, SJ Urbanski, PL Beck   +4 more
doaj   +1 more source

Use of Octreotide in the Acute Management of Bleeding Esophageal Varices

Canadian Journal of Gastroenterology, 1997
Acute hemorrhage from esophageal varices is a medical emergency; despite early diagnosis and treatment the associated hospital mortality remains high.
Daniel C Sadowski
doaj   +1 more source

Efficacy and safety of octreotide treatment for diazoxide‐unresponsive congenital hyperinsulinism in China

Pediatric Investigation, 2020
Importance Octreotide is an off‐label medicine for congenital hyperinsulinism (CHI), but is currently widely used for treatment of patients with CHI. Thus far, variable efficacy and adverse effects have been reported for octreotide. Objective The present
Bingyan Cao, Wu Di, Chang Su, Jiajia Chen, Xuejun Liang, Min Liu, Wenjing Li, Xiaoqiao Li, Chunxiu Gong   +8 more
doaj   +1 more source

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly [PDF]

, 2016
PURPOSE: Cushing’s disease (CD) and acromegaly are characterized by excessive hormone secretion resulting in comorbidities such as impaired glucose metabolism, diabetes and hypertension.
Silverstein, Julie M
core   +2 more sources

Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: the GETNE-TRASGU study [PDF]

, 2019
Artículo escrito por un elevado número de autores, sólo se referencian el que aparece en primer lugar, y los autores pertenecientes a la UAMSomatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well ...
Carmona Bayonas, Alberto, Marazuela, Mónica   +1 more
core   +1 more source